{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:43:56Z","timestamp":1792791836104,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group previously developed the EORTC Quality of Life Questionnaire (QLQ) Hodgkin Lymphoma 27. This paper reports the final results of an international study by the EORTC group to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N\u00a0= 381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27, and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (n\u00a0= 126) or responsiveness-to-change analyses (RCA) second measurement (n\u00a0= 98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its 4 scales (symptom burden, physical condition\/fatigue, emotional impact, and worries about health\/functioning). Test\u2013retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36%-83% reporting at least a few problems) compared with those who had completed treatment (19%-61% reporting at least a few problems). Prevalence of worries about health and functioning (reporting at least some worry) was similar for patients on treatment (51%-81%) vs those who had completed treatment (52%-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010841","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:44:25Z","timestamp":1695397465000},"page":"7045-7055","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1595-7262","authenticated-orcid":false,"given":"Simone","family":"Oerlemans","sequence":"first","affiliation":[{"name":"1Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[{"name":"2Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases Data Centre, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Shamieh","sequence":"additional","affiliation":[{"name":"3Department of Palliative Medicine, King Hussein Cancer Center, Amman, Jordan"},{"name":"4Faculty of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cardoso Borges","sequence":"additional","affiliation":[{"name":"5Department of Epidemiology and National Cancer Registry, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"de Jong","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Dong","sequence":"additional","affiliation":[{"name":"7JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lehmann","sequence":"additional","affiliation":[{"name":"8University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Malak","sequence":"additional","affiliation":[{"name":"9H\u00f4pital Ren\u00e9 Huguenin-Institut Curie- H\u00e9matologie, Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duska","family":"Petranovic","sequence":"additional","affiliation":[{"name":"10Clinical Hospital Center Rijeka, University of Rijeka, Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[{"name":"11Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[{"name":"12Hematology, Businco Hospital, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Molica","sequence":"additional","affiliation":[{"name":"13Azienda Ospedalier Ciaccio, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[{"name":"14Hematology, Oncology and Transfusion Medicine, Vilnius University Hospital Santaros Klinikos and Faculty of Medicine, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nagele","sequence":"additional","affiliation":[{"name":"15Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bredart","sequence":"additional","affiliation":[{"name":"16Institut Curie Psycho-Oncology Unit; Paris University, Psychopathology and Health Process Laboratory (UR 4057); PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Carvalho","sequence":"additional","affiliation":[{"name":"5Department of Epidemiology and National Cancer Registry, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal"},{"name":"17Clinical Research Unit, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliki","family":"Xochelli","sequence":"additional","affiliation":[{"name":"18Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Agelink van Rentergem","sequence":"additional","affiliation":[{"name":"19Department of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-9891","authenticated-orcid":false,"given":"Waleed","family":"Alrjoob","sequence":"additional","affiliation":[{"name":"3Department of Palliative Medicine, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mueller","sequence":"additional","affiliation":[{"name":"11Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Freitas","sequence":"additional","affiliation":[{"name":"20Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[{"name":"21York Trials Unit, University of York, York & Adelphi Values, Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien","family":"Creutzberg","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"22University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"van de Poll-Franse","sequence":"additional","affiliation":[{"name":"1Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"},{"name":"19Department of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"23Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"2023112721305769100_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/EDBK_200679","article-title":"New treatment algorithms in Hodgkin lymphoma: too much or too little?","volume":"38","author":"Spinner","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2023112721305769100_bib2","unstructured":"NKR Cijfers\n          . . 2022. Accessed 25 February 2022. http:\/\/www.cijfersoverkanker.nl."},{"key":"2023112721305769100_bib3","unstructured":"Howlader\n              N\n            , NooneAM, KrapchoM, . SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Accessed 25 February 2022. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"2023112721305769100_bib4","unstructured":"The Global Cancer Observatory\n          . Hodgkin Lymphoma. Accessed 21 June 2023. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/33-Hodgkin-lymphoma-fact-sheet.pdf."},{"issue":"11","key":"2023112721305769100_bib5","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol"},{"issue":"26","key":"2023112721305769100_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023112721305769100_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2023112721305769100_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/bjc.2013.779","article-title":"Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity","volume":"110","author":"Daniels","year":"2014","journal-title":"Br J Cancer"},{"issue":"18","key":"2023112721305769100_bib9","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2003.01.044","article-title":"Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133","volume":"21","author":"Ganz","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023112721305769100_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(09)70258-X","article-title":"Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial","volume":"10","author":"Heutte","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023112721305769100_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(16)30093-6","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group","volume":"17","author":"Kreissl","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2023112721305769100_bib12","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.19.03160","article-title":"Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group","volume":"38","author":"Kreissl","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023112721305769100_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-016-0515-6","article-title":"Health-related quality of life in Hodgkin lymphoma: a systematic review","volume":"14","author":"Linendoll","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2023112721305769100_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1008315525997","article-title":"Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms","volume":"10","author":"Loge","year":"1999","journal-title":"Ann Oncol"},{"issue":"9","key":"2023112721305769100_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-011-1274-4","article-title":"The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review","volume":"90","author":"Oerlemans","year":"2011","journal-title":"Ann Hematol"},{"issue":"14","key":"2023112721305769100_bib16","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1080\/10428194.2019.1641803","article-title":"Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors","volume":"60","author":"Trachtenberg","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023112721305769100_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bjh.15448","article-title":"Cognitive impairment in Hodgkin lymphoma survivors","volume":"182","author":"Trachtenberg","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2023112721305769100_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/0284186X.2016.1267404","article-title":"Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry","volume":"56","author":"Husson","year":"2017","journal-title":"Acta Oncol"},{"issue":"4","key":"2023112721305769100_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11764-014-0367-1","article-title":"The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry","volume":"8","author":"Oerlemans","year":"2014","journal-title":"J\u00a0Cancer Surviv"},{"issue":"3","key":"2023112721305769100_bib20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"2023112721305769100_bib21","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A\u00a0comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023112721305769100_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023112721305769100_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","article-title":"International development of four EORTC disease-specific Quality of Life Questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia","volume":"27","author":"van de Poll-Franse","year":"2018","journal-title":"Qual Life Res"},{"key":"2023112721305769100_bib24","unstructured":"Johnson\n              C\n            , AaronsonN, BlazebyJM, . EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules, Fourth Edition. EORTC. Accessed 2 May 2023. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/guidelines_for_developing_questionnaire-_final.pdf."},{"key":"2023112721305769100_bib25","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours","author":"Swerdlow","year":"2008"},{"issue":"5","key":"2023112721305769100_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"2023112721305769100_bib27","unstructured":"Kulis\n              D\n            , . EORTC Quality of Life Group Translation Procedure, Fourth Edition. EORTC. 2017. Accessed 2 May 2023. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/translation_manual_2017.pdf."},{"key":"2023112721305769100_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1472-6947-12-126","article-title":"The Computer-based Health Evaluation Software (CHES): a software for electronic patient-reported outcome monitoring","volume":"12","author":"Holzner","year":"2012","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"2023112721305769100_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"6","key":"2023112721305769100_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"6","key":"2023112721305769100_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2023112721305769100_bib32","first-page":"1","article-title":"\u201clavaan: an R package for structural equation modeling.\u201d","volume":"48","author":"Rosseel","year":"2012","journal-title":"J\u00a0Stat Softw"},{"key":"2023112721305769100_bib33","author":"Jorgensen","year":"2021"},{"key":"2023112721305769100_bib34","first-page":"23","article-title":"Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures","volume":"8","author":"Schermelleh-Engel","year":"2003","journal-title":"Methods Psychol Res"},{"issue":"2","key":"2023112721305769100_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1468-2389.1993.tb00092.x","article-title":"Exploratory factor analysis: a users\u2019 guide","volume":"1","author":"Ferguson","year":"1993","journal-title":"Int J Sel Assess"},{"issue":"3","key":"2023112721305769100_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of test","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika"},{"key":"2023112721305769100_bib37","author":"de Vet HCW","year":"2011"},{"issue":"1","key":"2023112721305769100_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","article-title":"Forming inferences about some intraclass correlation coefficients","volume":"1","author":"McGraw","year":"1996","journal-title":"Psychol Methods"},{"issue":"1","key":"2023112721305769100_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality criteria were proposed for measurement properties of health status questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J\u00a0Clin Epidemiol"},{"key":"2023112721305769100_bib40","author":"Fayers","year":"2007"},{"key":"2023112721305769100_bib41","volume-title":"R: A Language and Environment for Statistical Computing","year":"2013"},{"key":"2023112721305769100_bib42","author":"Cohen","year":"1977"},{"issue":"9","key":"2023112721305769100_bib43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s11912-022-01283-3","article-title":"Quality of life and survivorship in lymphoma","volume":"24","author":"Rosenthal","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2023112721305769100_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.18072","article-title":"International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia","volume":"197","author":"Oerlemans","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"2023112721305769100_bib45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(18)30141-4","article-title":"Patient-reported outcomes: an essential component of oncology drug development and regulatory review","volume":"19","author":"Basch","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023112721305769100_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023112721305769100_bib47","first-page":"32","article-title":"Fear of cancer recurrence: a practical guide for clinicians","volume":"32","author":"Butow","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"9","key":"2023112721305769100_bib48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jval.2017.08.2236","article-title":"The use of the EORTC item library to supplement EORTC Quality of Life Instruments","volume":"20","author":"Kulis","year":"2017","journal-title":"Value Health"},{"key":"2023112721305769100_bib49","unstructured":"European Organisation for Research and\n          . Treatment of Cancer (EORTC) Quality of Life Group (QLG). Accessed 2 May 2023. http:\/\/groups.eortc.be\/qol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7045\/2110443\/blooda_adv-2023-010841-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7045\/2110443\/blooda_adv-2023-010841-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T21:31:26Z","timestamp":1701120686000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/7045\/497977\/International-validation-of-a-health-related"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":49,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010841","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}